Biotech & Genomic Medicine▲
Six Biotech Stocks Deliver Stunning Gains of Up to 700%
Six biotech stocks profiled by RTTNews have delivered stunning gains for patient investors, with Inhibrx Biosciences surging as much as 746% since its profile was published on July 8, 2025. Palvella Therapeutics rose up to 505% from its March 10, 2025 profile, driven by positive trial results and an FDA rolling review for its rare-disease therapy. MBX Biosciences gained up to 363% since June 18, 2025, following encouraging data from multiple clinical programs. Protagonist Therapeutics advanced as much as 204% from its January 6, 2025 profile after FDA approval of its psoriasis drug. Absci Corp. climbed up to 290% since September 12, 2025, on positive interim data for its AI-designed hair-loss treatment. Belite Bio increased up to 187% from its September 15, 2025 profile, supported by a completed rolling NDA submission for its retinal-disease therapy.